TG Therapeutics Inc. (TGTX) Rating Reiterated by Roth Capital
TG Therapeutics Inc. (NASDAQ:TGTX)‘s stock had its “buy” rating restated by Roth Capital in a research note issued on Friday. They presently have a $33.00 target price on the biopharmaceutical company’s stock. Roth Capital’s price objective would suggest a potential upside of 400.76% from the company’s previous close.
Several other analysts also recently issued reports on TGTX. Zacks Investment Research downgraded shares of TG Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 14th. S&P Equity Research decreased their price objective on shares of TG Therapeutics from $7.15 to $6.40 in a research note on Wednesday, August 24th. FBR & Co reissued a “buy” rating on shares of TG Therapeutics in a research note on Monday, September 19th. Finally, Brean Capital reissued a “buy” rating and issued a $28.00 price objective on shares of TG Therapeutics in a research note on Thursday, October 6th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $21.21.
TG Therapeutics (NASDAQ:TGTX) opened at 6.59 on Friday. TG Therapeutics has a 12-month low of $5.41 and a 12-month high of $14.87. The stock’s market cap is $358.87 million. The firm’s 50 day moving average price is $7.39 and its 200-day moving average price is $7.37.
TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.29) by $0.04. TG Therapeutics had a negative return on equity of 58.77% and a negative net margin of 40,142.11%. Equities research analysts anticipate that TG Therapeutics will post ($1.22) earnings per share for the current fiscal year.
Several hedge funds have recently bought and sold shares of TGTX. BlackRock Advisors LLC increased its position in shares of TG Therapeutics by 14.5% in the second quarter. BlackRock Advisors LLC now owns 18,131 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 2,296 shares during the period. Mariner Wealth Advisors LLC increased its position in shares of TG Therapeutics by 4.4% in the second quarter. Mariner Wealth Advisors LLC now owns 19,086 shares of the biopharmaceutical company’s stock worth $116,000 after buying an additional 800 shares during the period. SECOR Capital Advisors LP acquired a new position in shares of TG Therapeutics during the second quarter worth approximately $187,000. Emerald Acquisition Ltd. acquired a new position in shares of TG Therapeutics during the second quarter worth approximately $190,000. Finally, Rhumbline Advisers increased its position in shares of TG Therapeutics by 9.0% in the second quarter. Rhumbline Advisers now owns 37,547 shares of the biopharmaceutical company’s stock worth $228,000 after buying an additional 3,107 shares during the period. 54.66% of the stock is owned by hedge funds and other institutional investors.
About TG Therapeutics
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Company is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes.
Receive News & Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.